Summary of Study ST000445

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000343. The data can be accessed directly via it's Project DOI: 10.21228/M8JS49 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000445
Study TitleFollicular fluid lipidomics reveals lipid alterations by LH addition during IVF cycles
Study SummaryPurpose Ovulation induction protocols are key components for performing assisted reproduction treatments successfully. The objective of the present study was to estimate how LH addition to controlled ovarian stimulation protocols may affect the follicular fluid lipid profile of women undergoing in vitro fertilization treatment. Methods We conducted the study using 28 self-paired samples, 14 per group. The patients received FSH during their first cycle of ovarian stimulation (FSH group). If treatment did not result in pregnancy, the same patients returned for a new cycle and received stimulus with the addition of LH to the previous protocol (Low-dose-LH group). Lipidomics analysis was performed by UPLC-MSE mass spectrometry. Potential lipid biomarkers were identified by the software Progenesis QI. Statistical analysis was performed using the SPSS 18.0 and MetaboAnalyst 2.0 software.
Institute
Universidade Federal de Sao Paulo
DepartmentSurgery
LaboratoryCentro de Pesquisa em Urologia
Last NameDa Costa
First NameLivia
AddressRua Embau 231 - Vila Clementino, Sao Paulo, Sao Paulo, 04039060, Brazil
Emailliviadovale@hotmail.com
Phone551138074062
Submit Date2016-07-25
Num Groups2
Total Subjects28
Num Females14
Study CommentsThe groups consists of the same 14 women submitted to two different controlled ovarian stimulation protocols (FSH or LH group)
Raw Data AvailableYes
Raw Data File Type(s)raw(Waters)
Analysis Type DetailLC-MS
Release Date2016-09-23
Release Version1
Livia Da Costa Livia Da Costa
https://dx.doi.org/10.21228/M8JS49
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:TR000480
Treatment Summary:To induce follicular growth, each of the eligible 14 patients received both rFSH 225 IU alone (Gonal F® [Merck-Serono, Darmstadt, Germany]) (FSH group) and rFSH 225 IU + hMG 75 IU (Menopur® [Ferring, Kiel, Germany]) (Low-dose-LH group) starting on cycle day 2 in two separate cycles (i.e. each patient acted as her own control). Sequential transvaginal ultrasounds were performed from stimulation day 5 onwards. Daily doses of GnRH antagonist analog cetrorelix acetate 0.25 mg (Cetrotide® [Merck-Serono, Darmstadt, Germany]) were administered in both groups when the leading follicle reached a mean diameter of 13 mm until the stimulation day 7, or from day 8. When at least one follicle was greater than 17 mm, 250 mcg of human chorionic gonadotropin (hCG) (Ovidrel® [Merck-Serono, Darmstadt, Germany]) was administered, and oocyte retrieval was scheduled 35-36 hours later.
Treatment:Two types of controlled ovarian stimulation
Treatment Compound:Exogenous gonadotropins to induce follicular growth
  logo